Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Leerink Partners Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by Leerink Partners from $641.00 to $824.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Partners’ target price suggests a potential upside of 2.55% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Finally, Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $801.70.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $803.48 on Monday. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a market cap of $82.73 billion, a P/E ratio of 19.86, a P/E/G ratio of 1.37 and a beta of 0.21. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $675.79 and its 200-day moving average price is $713.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the firm posted $12.81 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $482,400. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 in the last three months. 6.97% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. Insigneo Advisory Services LLC increased its position in shares of Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC lifted its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 14 shares during the last quarter. Arjuna Capital boosted its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares during the period. TD Private Client Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares during the last quarter. Finally, MCF Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.